US negotiations for first round of drugs reveal $6bn in Medicare savings
The Centers for Medicare and Medicaid Services stated that savings of $3.7bn are predicted in the first year when negotiated drug prices apply.
Pricing and Market Access
Colombia’s president signs law to strengthen pharmaceutical sector
Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy
The US Biosecure Act threatens to destabilise the pharmaceutical industry
UK’s antibiotic subscription funding model – a route to market sustainability?
Ukraine: a market access review over two years of war
AIFA’s horizon scanning 2024 predictions suggest an influx of ATMPs
The privileged status of orphan medicines in Germany
